27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
This study provides preliminary evidence that falls among community-dwelling older adults are associated with factors such as age, female gender, fear of falling, history of falls, unclear vision, depression, and balance disorders. 4 key findings →
Design: systematic review Participants: 31 Evidence: high
Full summary, score breakdown and related studies → Original source
Forty-eight studies from 18,456 screened abstracts (Dementia: n = 2,516, Control: n = 1,224) met inclusion criteria for the systematic review. 5 key findings →
Design: systematic review Participants: 2,516 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
These pathological changes lead to widespread neuronal damage, significantly impacting daily functioning and quality of life. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Our results provide the first empirical evidence of CF in China. 5 key findings →
Participants: 5,708 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Geroscience, the new interdisciplinary field that aims to understand the relationship between aging and chronic age-related diseases (ARDs) and geriatric syndromes (GSs), is based on epidemiological evidence and experimental data that aging is the major risk factor for such pathologies and assumes that aging and ARDs/GSs share a common set of basic biological mechanisms. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Oldest-old care recipients were more impaired in cognitive function and instrumental ADL; there was no difference in behavior and basic ADL. 5 key findings →
Participants: 458 Evidence: low
Full summary, score breakdown and related studies → Original source
The early and accurate diagnosis of Alzheimer's Disease and Frontotemporal Dementia remains a critical challenge, particularly with traditional machine learning models which often fail to provide transparency in their predictions, reducing user confidence and treatment effectiveness. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Postoperative cognitive dysfunction (POCD) is a common and serious postoperative complication in elderly patients, affecting cognitive function and quality of life. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The incidences of POD and sarcopenia in geriatric hip fracture patients are high. 4 key findings →
Participants: 234 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Over the last 10 years, there has been a growing interest in the relationship between gut microbiota, the brain, and neurologic-associated affections. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The model achieves accuracy rates of 94% on the brain tumor dataset, 81% on the augmented Alzheimer dataset, and 93% on the third dataset, underscoring its capability to differentiate various neurological conditions. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Carers' knowledge about dementia was moderate overall, with higher scores among those with greater education and previous dementia exposure. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Thirty-four studies were included. Psychosocial interventions generating enrichment among dyads mainly involved supporting dyadic engagement in shared activities, carer education or training, or structural change to the environment around PLWD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Successful back-translating clinical biomarkers and molecular imaging methods of Alzheimer's disease (AD), including positron emission tomography (PET), are very valuable for the evaluation of new therapeutic strategies and increase the quality of preclinical studies. 18 F-Fluorodeoxyglucose (FDG)-PET and 18 F-Florbetaben-PET are clinically established biomarkers capturing two key pathological features of AD. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The burden of perioperative organ injury in China is significant even at a national level. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Lipoprotein(a) [Lp(a)] is a genetically determined lipoprotein particle composed of apolipoprotein B-100 covalently linked to apolipoprotein(a) [apo(a)] via a disulfide bond. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease (AD) and related tauopathies such as frontotemporal dementia (FTD) or traumatic brain injury (TBI) are neurodegenerative disorders characterized by progressive loss of memory and cognitive function. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The latter often experience a loss of functional independence and geriatric syndromes including falls, undernutrition and neurocognitive disorders (1) requiring significant care that generates health expenditure. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →